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Aims: Pulmonary hypertension (PH) and pulmonary vascular disease (PVD) are 
common and associated with adverse outcomes in heart failure with preserved ejection 
(HFpEF). Little is known about the impact of PVD on the pathophysiology of exercise 
intolerance.  
Methods and Results: HFpEF patients (n=161) with elevated pulmonary capillary 
wedge pressure (≥15 mmHg) at rest were classified into 3 groups: non-PH-HFpEF 
(n=21); PH but no PVD (isolated post-capillary PH, IpcPH; n=95); and PH with PVD 
(combined post- and pre-capillary PH, CpcPH; n=45). At rest, CpcPH-HFpEF patients 
had more right ventricular dysfunction and lower pulmonary arterial (PA) compliance 
compared to all other groups. While right atrial pressure (RAP) and left ventricular 
transmural pressure (LVTMP) were similar in HFpEF with and without PH or PVD at 
rest, CpcPH-HFpEF patients demonstrated greater increase in RAP, enhanced 
ventricular interdependence, and paradoxical reduction in LVTMP during exercise, 
differing from all other groups (p<0.05). Lower PA compliance was correlated with 
greater increase in RAP with exercise. During exercise, CpcPH-HFpEF patients 
displayed an inability to enhance cardiac output, reduction in forward stroke volume, 
and blunted augmentation in RV systolic performance, changes that were coupled with 
marked limitation in aerobic capacity. 
Conclusion: HFpEF patients with pulmonary vascular disease demonstrate unique 
hemodynamic limitations during exercise that constrain aerobic capacity, including 
impaired recruitment of LV preload due to excessive right heart congestion and blunted 
right ventricular systolic reserve. Interventions targeted to this distinct pathophysiology 




Heart failure with preserved ejection (HFpEF) accounts for approximately half of 
all heart failure patients, affecting millions worldwide.1 Although there are features 
common to all HFpEF patients, there may be substantial pathophysiologic heterogeneity 
as well.2 HFpEF is initially defined by an elevation in left-sided filling pressures, but 
many patients progress to develop pulmonary vascular disease (PVD) secondary to 
chronic left heart congestion.3-14 This cohort experiences worse outcomes when 
compared to HFpEF patients with isolated left heart disease, but the mechanisms 
explaining this observation remain poorly understood.3-14  
Patients with HFpEF universally complain of exertional intolerance, but the 
causes may differ between patients with different phenotypes. Exercise introduces an 
impressive stress to the right heart and lungs, where elevations in venous return 
increase pulmonary blood volume by 50% while increasing lung blood flow 300%.15 The 
healthy pulmonary vasculature is a high compliance, low resistance circuit that can 
readily accommodate these marked increases in blood volume and flow.4, 16 However, 
this reserve may be compromised in patients with HFpEF and PVD, which may lead to 
important differences compared to HFpEF patients with left heart disease and no PVD. 
We performed invasive hemodynamic exercise testing with expired gas analysis 
in a well-defined cohort of HFpEF patients with and without PVD. We hypothesized that 
the presence of PVD in HFpEF would compromise the ability of the right heart and 
lungs to accommodate increased blood flow during exercise, increasing ventricular 





Consecutive patients who underwent invasive hemodynamic exercise testing at 
the Mayo Clinic in Rochester, MN between 2006 and 2016 were identified. The Mayo 
Clinic Institutional Review Board approved the study and all subjects provided written 
informed consent. All authors had full access to the data and take full responsibility for 
its integrity. 
HFpEF was defined by the presence of typical symptoms (exertional dyspnea 
and fatigue), left ventricular ejection fraction (LVEF) ≥50% and elevated left-sided filling 
pressures at rest (pulmonary capillary wedge pressure [PCWP] >15 mmHg). HFpEF 
patients with normal resting PCWP, but elevated PCWP on exercise were not included. 
To investigate exercise hemodynamics according to the presence of PVD, we divided 
HFpEF patients into pulmonary hypertension (PH) subgroups according to published 
recommendations: 1) non-PH (mean pulmonary artery pressure [PAP] <25 mmHg), 2) 
PH with no PVD (isolated post-capillary PH, IpcPH; mean PAP ≥25 mmHg with 
pulmonary vascular resistance [PVR] ≤3.0 Wood units [WU] and diastolic pressure 
gradient [DPG] <7 mmHg), and 3) PH with PVD (combined post- and pre-capillary PH, 
CpcPH; mean PAP ≥25 mmHg with PVR >3.0 and/or DPG ≥7 mmHg).17  
Patients with LVEF <50%, primary right-sided HF, valvular heart disease 
(>moderate left-sided regurgitation and/or >mild stenosis), unstable coronary artery 
disease or recent revascularization, constrictive pericarditis, high-output heart failure, 






Echocardiography was performed at rest in a blinded fashion according to the 
guidelines of the European Association of Cardiovascular Imaging and the American 
Society of Echocardiography to assess LV diastolic function, mass and severity of 
valvular heart disease.18, 19 Left ventricular EF was assessed using quantitative 
measures based upon optimal images in each patient, including 2-dimensional 
echocardiography using the Quinones formula from the parasternal views (n=107), the 
2-dimensional biplane volumetric Simpson method (n=23), M-mode (n=2) or visual 
qualitative assessment (n=29) if quantitative measurements could not be made. Using 
RV-focused views, RV basal and mid-cavity dimensions were measured at end-diastole, 
and RV end-diastolic and end-systolic areas were traced to calculate fractional area 
change (FAC = [RV end-diastolic area – end-systolic area] / end-diastolic area x 100).20 
Pericardial restraint and ventricular interaction were assessed by the LV eccentricity 
index measured at end-diastole as recently described.21 An LV eccentricity index >1.0 
indicates a leftward septal shift due to right-sided overload and enhanced ventricular 
interdependence. 
 
Cardiac catheterization protocol 
Patients were assessed on chronic medications, in fasted state, after minimal 
sedation and in supine position, without knowledge of echocardiography data, as 
previously described.21-25 Right heart catheterization was performed through a 9F 
sheath via the right internal jugular vein at both rest and with exercise, with 
simultaneous directly measured oxygen consumption (VO2) using expired gas analysis 
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(MedGraphic, St. Paul, MN). Right atrial pressure (RAP), PAP and PCWP were 
recorded at end-expiration, using the mean of 3 beats. Pressure tracings were 
digitized (240 Hz) and stored for offline analysis, performed in a blinded fashion. The LV 
transmural pressure (LVTMP), which quantifies the net distending pressure that 
determines LV preload, was calculated as PCWP minus RAP.21, 26-29  
Arteriovenous oxygen difference (A-VO2diff) was determined from directly 
measured arterial and mixed venous O2 contents from blood sampling 
(saturation*hemoglobin*1.34*10). Cardiac output (CO) was determined by the direct 
Fick method (CO = VO2/A-VO2diff) and indexed for body surface area to calculate 
cardiac index (CI). Pulmonary vascular resistance (PVR= [mean PAP – PCWP]/CO) 
and systemic vascular resistance (SVR= [mean arterial blood pressure – RAP]/CO), 
stroke volume (SV=CO/heart rate), systemic and pulmonary pulse pressure, and 
diastolic pressure gradient (DPG=PA diastolic - PCWP) were calculated. Pulmonary 
arterial compliance (PAC) and total arterial compliance (TAC) were calculated 
(PAC=SV/pulmonary pulse pressure; TAC=SV/systemic pulse pressure, respectively).24, 
30 Total pulmonary resistance (TPR) was calculated as the quotient of mean PA 
pressure and CO.31 End-systolic pressure (ESP) was taken as 0.9*systolic blood 
pressure. Systemic and pulmonary arterial elastance (Ea-S, Ea-P) were calculated as 
ESP/SV and PA systolic pressure/SV, respectively. 
Following rest measures, patients engaged in supine cycle ergometry starting at 
20 Watt workload and increasing in 10 to 20 Watt increments (3 minutes per stage) until 
subject-reported exhaustion. Hemodynamic data were again acquired at peak exercise 




Data are reported as mean  standard deviation (SD), median (25th, 75th 
percentile) or numbers (percentages). For each parameter, between-group differences 
were first assessed using one-way ANOVA, Kruskal-Wallis test, or χ2 test, as 
appropriate. Then, the Tukey honestly-significant-difference test or Steel-Dwass test 
were applied (as appropriate) to account for multiple comparisons between the 3 
groups. No adjustment was made to account for multiple hypotheses testing among the 
different hemodynamic parameters studied. Correlations were calculated using 
Spearman’s or Pearson’s correlation, when appropriate. An interaction term was applied 
to examine whether correlations differed between two groups. To accomplish this a 
linear model was fit where dependent variable Y is modeled by the continuous variable 
X (independent variable of interest), a categorical variable (group) and the interaction 
between the two X variables (X*group). P-values are 2-sided and predefined 
significance level was <0.05. Analyses were performed in JMP 10.0.0 (SAS Institute, 
Cary, NC, USA). 
 
RESULTS 
Of patients with HFpEF (n=161), the vast majority (n=140, 87%) displayed PH 
(i.e. mean PA pressure≥25 mmHg) at rest. Of this group, 68% (n=95) displayed IpcPH 
and 32% (n=45) had CpcPH-HFpEF. All CpcPH patients displayed elevated PVR (>240 
dynes/sec*cm5) but only 11 (24%) displayed elevated DPG. Of the total cohort, 50% 
were examined from 2006-2013 and 50% from 2013-2016. Sensitivity analysis 
performed separately among patients in the two eras showed similar results, suggesting 
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that the length of the inclusion period did not significantly influence the results 
(Supplemental Table 1).  
Age, sex, body mass index, and body surface area were similar across groups 
(Table 1). The prevalence of AF and NT-proBNP levels were highest in CpcPH-HFpEF 
but other comorbidities and medication use were similar across groups. Baseline 
characteristics of the study cohort were similar to those from HFpEF patients enrolled in 
contemporary clinical trials (Supplemental Table 2).  
Cardiac structure, Function and Hemodynamics at rest 
Left ventricular dimensions, mass and EF were similar across HFpEF groups 
(Table 1). HFpEF patients with PH displayed higher E/e’. Patients with CpcPH displayed 
more RV systolic dysfunction compared to the other groups, reflected by lower FAC 
(Figure 1A). RV dimensions tended to be increased in CpcPH and tricuspid 
regurgitation was more prevalent. The LV eccentricity index tended to be increased in 
CpcPH-HFpEF patients with PH, indicating greater flattening of the interventricular 
septum towards the left ventricle at rest and thus greater ventricular interdependence 
(Table 1). 
There were no differences in heart rate or blood pressures between the groups 
(Table 2). RAP was similar among HFpEF patients with and without PH at rest. There 
were no statistically significant differences in RAP/PCWP ratio and LV transmural 
pressure between groups at rest.  
Patients with CpcPH-HFpEF displayed more deranged RV-PA coupling, with 
greater reduction in RV FAC and more RV dilatation as resting PVR increased (Figures 
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1B-C). Patients with CpcPH-HFpEF also displayed increased Ea-P, lower PA 
compliance, and reduced stroke volume and cardiac index at rest, with a higher AVO2 
difference (Table 2). Patients with HFpEF and PH (regardless of PVD) displayed 
increased RV stroke work index, reflecting the greater pressure-volume work needed to 
eject blood through the pulmonary vasculature in the setting of PH. CpcPH-HFpEF 
patients also displayed increased systemic vascular stiffening, with higher SVR and Ea-
S, and lower total arterial compliance (Table 2).  
Exercise hemodynamics 
Exercise capacity was reduced in HFpEF patients with PH, evidenced by lower 
work load achieved and decreased peak VO2 (Table 3). Cardiac output, which by 
definition is equal to venous return to the right heart at steady state, increased similarly 
with exercise in Non-PH and IpcPH-HFpEF, but was lower for any exercise workload in 
CpcPH-HFpEF (Figure 2A). All groups displayed similar absolute increases in PCWP 
with exercise, though PCWP elevation occurred at lesser cardiac output or venous 
return in CpcPH-HFpEF (Table 3, Figure 2B).  
Pulmonary artery pressures increased in all groups with exercise, but the 
greatest increases were observed in the CpcPH group, with higher pressures relative to 
blood flow (Table 3, Figure 2C). Patients in the CpcPH-HFpEF group experienced 
greater reduction in PA compliance on exercise along with higher exercise PVR and Ea-
P, in keeping with impaired pulmonary vascular reserve (Table 3, Figure 2D).  
Despite similar RAP at rest, both PH-HFpEF groups developed greater increases 
in RAP during exercise (Table 3). The intolerance of the right heart and pulmonary 
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circulation to elevation in venous return during exercise was most dramatic in CpcPH-
HFpEF (Figure 3A).  
Increases in right heart congestion may compromise left heart filling in the setting 
of ventricular interdependence. Patients with Non-PH HFpEF and IpcPH-HFpEF 
displayed an increase in LV transmural filling pressures, with stable RAP/PCWP ratio 
during exercise, indicating that left heart congestion was the major pathophysiological 
driver (Figures 3B, 4B). In striking contrast, patients with CpcPH-HFpEF developed a 
paradoxical decrease in LV transmural pressure as venous return to the right heart 
increased during exercise (Figure 3B), with an increase in RAP/PCWP ratio (Figure 4B).  
The reduction in LV transmural pressure was increased as exercise PVR and 
transpulmonary gradient increased, indicating that left heart underfilling was directly 
related to the severity of pulmonary vascular disease present (Figure 3C, 3D). This was 
likely related to greater increase in RAP, which were amplified to greater extent as PA 
compliance decreased in CpcPH-HFpEF (Figure 4A).  
Thus, even as hydrostatic pressures in the pulmonary capillaries increased with 
exercise in CpcPH-HFpEF patients, there was effective under-distention of the LV. This 
reduction in LV transmural pressure was coupled with the impairment in cardiac output 
in CpcPH-HFpEF (Figure 2A), explained by a reduction in stroke volume, which actually 
decreased with exercise in CpcPH-HFpEF, even as PA pulse pressure increased, 
emphasizing the marked limitation in PA compliance (Figure 4C). Right ventricular 
systolic reserve was impaired in both of the PH-HFpEF groups, manifest by a blunted 





This is the first comprehensive evaluation of exercise hemodynamics in a well-
defined cohort of patients with invasively-verified HFpEF with and without pulmonary 
vascular disease (PVD). We demonstrate that HFpEF patients with CpcPH displayed 
multiple features consistent with more advanced HF, including greater RV dysfunction, 
higher natriuretic peptide levels, and greater burden of atrial fibrillation. CpcPH-HFpEF 
patients displayed more abnormal RV-PA arterial interaction at rest, with greater 
chamber dilation and dysfunction as pulmonary vascular resistance increased. Despite 
similar biventricular filling pressures at rest, patients with CpcPH-HFpEF developed 
more dramatic increases in right heart filling pressures as venous return increased 
during exercise, resulting in enhanced ventricular interdependence, which compromised 
the transmural distending pressures that drive LV chamber filling. Together with 
reduced RV contractile reserve, this led to decreases in stroke volume and blunted 
ability to augment cardiac output with exercise in patients with CpcPH-HFpEF, which 
was associated with profound impairment in aerobic capacity. These data show that 
HFpEF patients with PVD demonstrate unique pathophysiologic features brought about 
by the stress of exercise that distinguish them from HFpEF patients without PVD, 
including impaired ability to enhance blood flow through the lungs, greater right heart 
congestion, failure to optimally utilize Frank-Starling reserve in the LV due to ventricular 
interaction, and limited capacity to augment RV systolic performance (Figure 5). These 
pathophysiologic insights have important implications for clinical care and for the design 




Pulmonary vascular disease in HFpEF 
Accumulating evidence supports the idea that there may be pathophysiologically 
unique phenotypes within the broader population of patients with HFpEF.2 The 
presence of PH and PVD appears to identify one such phenotype of importance.5-11 
Prior studies have begun to characterize PVD in HFpEF clinically and hemodynamically 
based upon resting data.10, 12, 14 Similar to the current data, these studies demonstrated 
that the presence of PVD in patients with HFpEF is associated with reduced exercise 
capacity, more severe RV dysfunction, and worse outcomes, but the mechanisms have 
remained unclear.   
We observed that PVD in HFpEF is associated with more severe systemic 
arterial disease, reflected by higher mean vascular resistance and arterial elastance and 
lower total arterial compliance in patients with CpcPH. This might be related in part to 
interdependence between the great vessels.32 Alternatively, combined systemic and PA 
stiffening may be related to widespread loss of NO bioavailability in both the lungs and 
systemic vasculature.33 Systemic vascular stiffening in HFpEF is correlated with more 
severe exercise-induced pulmonary hypertension, and this is partially reversible with 
acute administration of NO providing therapies.30 These data support the hypothesis 
that endothelial dysfunction and NO deficiency plays an important role in both the 
pulmonary and systemic vasculature in patients with HFpEF,34 and that therapies 
targeting NO metabolism may hold great promise for patients with HFpEF and PVD. 
Recent data also indicate that there may be substantial pulmonary vascular remodeling 
in patients with HFpEF, which may require additional antiproliferative therapies to 
restore pulmonary vascular reserve.35 
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Exercise Unmasks a Unique Pathophysiology in HFpEF with PVD 
We observed distinct hemodynamic responses to exercise in HFpEF patients 
that varied according to the presence or absence of PVD, many of which were related to 
the phenomenon of ventricular interdependence. We speculate that this was related to 2 
key factors: an inability of the lung vasculature to accommodate increased blood volume 
and flow due to vasoconstriction and vascular remodeling, and impairments in right 
ventricular function that limited the ability to eject blood through the higher impedance 
pulmonary circulation as metabolic demand for systemic perfusion increases.  
The RV and LV are connected in series, so RV output affects LV filling in this 
direct way. However, the two ventricles also occupy the same space in the cardiac 
fossa and may also interact in parallel.26-28 Ventricular interdependence refers to the 
phenomenon whereby changes in pressure, filling and volume in one chamber 
influences these characteristics in the other chamber. Diastolic ventricular interaction 
may be observed in patients with right heart failure due to acute pulmonary embolism, 
or severe isolated tricuspid regurgitation, where the dilated right ventricle out-competes 
the left ventricle for space, and the interventricular septum bows from right to left, 
leading to “underloading” of the LV.27, 29 A similar relationship is also observed in 
patients with the obese phenotype of HFpEF, where abnormal RV-PA interaction 
synergizes with volume overload and increased epicardial fat to amplify ventricular 
interaction.21 
 Exercise poses a profound stress on the heart and lungs: blood is rapidly 
redistributed from the abdomen and extremities to the thorax, leading in a 50% increase 
in lung blood volume and 300% increase in pulmonary blood flow in the healthy adult.15 
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Because patients with CpcPH-HFpEF display pulmonary vascular disease that may limit 
this reserve, we hypothesized that the increase in systemic venous return 
accompanying exercise might overwhelm the right heart and lungs, leading to more 
severe pulmonary hypertension, greater RV-PA uncoupling, and heightened right sided 
congestion, setting the stage for conditions that promote enhanced interdependence.  
Consistent with this hypothesis, we found that lower PA compliance was 
associated with more exuberant increases in RA pressures in CpcPH-HFpEF patients 
during exercise (Figure 4), while greater elevations in PVR and transpulmonary gradient 
were correlated with greater reduction in LV transmural pressure (Figure 3), which more 
accurately reflects the true LV distending pressure or preload.27, 28 The combination of a 
reduction in LV transmural distending pressure and blunted RV contractile reserve 
observed in the CpcPH-HFpEF group led to a striking reduction in stroke volume during 
exercise and impairment in cardiac output heightened venous return (Figure 4).    
Clinical implications 
The treatment of HFpEF is an enormous unmet public health need and there 
have been valid concerns that many of the previous neutral trials might have been 
positive if the right patients had been enrolled. The common existence of PVD in HFpEF 
and its association with adverse prognosis has stimulated new interest in novel 
therapies targeting the pulmonary vasculature in this disorder.6, 7 The present data 
identifying unique features to the pathophysiology of PVD provide further support for 
conducting trials targeting pulmonary vascular structure and function in HFpEF. For the 
design of such therapies, it may be best to first conduct smaller mechanistic, phase 1 
and 2 trials to specifically investigate safety and signals of efficacy for specific drugs, 
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using invasive hemodynamic endpoints. Multiple such trials targeting pulmonary 
vasoconstriction and remodeling are currently underway (NCT 03153111, 02742129, 
03043651, 02885636, 03015402, and 02744339).  
If candidate drugs demonstrate safety and signal of efficacy in smaller invasive 
trials, larger clinical trials may then be conducted without the need for invasive 
hemodynamic phenotyping, using non-invasive surrogate criteria, for example relying 
upon imaging and biomarkers, and using more easily measurable endpoints such as 6 
minute walk distance and quality of life assessment. This sort of staged approach may 
hold the greatest potential to deliver the right therapy to the patient most likely to derive 
benefit from this therapy, rather than the “one size fits all” approach that has been used 
unsuccessfully thus far in HFpEF. 
The current data suggest that there may be other therapeutic targets in HFpEF-
PVD that merit study. The enhanced ventricular interdependence that occurs during 
exercise in HFpEF-PVD provides a theoretical basis for reducing pericardial restraint in 
order to preserve stroke volume reserve and improve cardiac output, similar to what is 
observed with pulmonary embolism.27, 36 In this regard, we have recently shown in 
animals without PVD that limited anterior pericardial resection abrogates the increase in 
cardiac filling pressures with volume loading, improving Frank-Starling reserve.37 
However, because pericardial resection can promote eccentric remodeling,38 and 
because we observed greater RV dilation with increasing PVR, it might be important to 
treat pulmonary vascular disease in tandem with interventions targeted to the pericardial 
restraint in patients with HFpEF and PVD. Right ventricular contractile reserve was also 
impaired with exercise in this study, in agreement with previous studies performed in 
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HFpEF patients without substantial PVD,24, 39 and this also supports testing new 
therapies that can improve RV function and functional reserve to improve clinical status 
in CpcPH HFpEF.  
There is controversy on the best method to define the entity of CpcPH. Current 
guidelines recommend the use of either PVR or DPG criteria.17 We observed that all of 
the CpcPH patients displayed elevated PVR, yet only a minority demonstrated an 
elevated DPG. Prior studies have shown that DPG does not predict survival in HF,6 and 
the current data show that DPG is not superior to PVR to identify patients with this 
characteristic pathophysiology on exercise. Further research is needed to investigate 




This study was single center and all patients were referred for right heart 
catheterization, introducing selection bias. However, the baseline characteristics are 
similar to what is seen in general HFpEF populations enrolled in recent clinical trials 
(Supplemental Table 2). The inclusion period for the study was extensive, but sensitivity 
analysis restricted to older and more recently-evaluated patients revealed similar results 
(Supplemental Table 1). Although the majority of patients had a quantitative 
assessment of LV ejection fraction, in a minority of patients LV ejection fraction was 
assessed qualitatively, and this could compromise the accuracy of LVEF assessment. 
Echocardiography was not performed during exercise. A relatively small number of 
patients with significant pulmonary vascular disease were included in the analysis, yet 
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multiple significant differences were identified. We did not include patients with early 
stage HFpEF (elevated PCWP during exercise but not at rest),40 because the PH 
subtypes are currently only classified based on resting hemodynamics.17 Further 
research is needed to characterize pulmonary vascular responses to exercise in 
patients with early stage HFpEF.7 
 
Conclusions 
Pulmonary vascular disease in HFpEF leads to unique pathophysiologic 
consequences during the stress of exercise, including inadequate PA vasodilation, 
greater right heart congestion, left heart underfilling, heightened ventricular 
interdependence, and impaired right ventricular reserve. These limitations markedly 
sabotage the ability of the heart to increase stroke volume and cardiac output during 
exercise, leading to profound limitations in aerobic capacity. Interventions targeted to 
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Figure 1: Right ventricular function and size at rest. (A) At rest, heart failure with 
preserved ejection fraction (HFpEF) patients with combined post- and pre-capillary 
pulmonary hypertension (CpcPH) displayed the lowest right ventricular fractional area 
change (RV FAC) compared to other groups. (B-C) Higher pulmonary vascular 
resistance (PVR) was associated with decreased FAC and with increased RV size in 
CpcPH-HFpEF, while these associations were absent in HFpEF patients with isolated 
post-capillary PH (IpcPH). Error bars reflect SEM. †p<0.05 vs Non PH-HFpEF; and 
#p<0.05 vs IpcPH-HFpEF.  
 
Figure 2: Changes in central pressures with exercise. (A) Baseline and peak 
exercise for cardiac output. (B-C) Pulmonary capillary wedge pressure (PCWP) and 
mean pulmonary artery pressure (PAP) and as a function of venous return. (D) As 
compared to both Non PH- and IpcPH-HFpEF, CpcPH-HFpEF displayed greater 
increase in pulmonary arterial elastance (Ea-P) during exercise.  Error bars reflect SEM. 
†p<0.05 vs Non PH-HFpEF; and #p<0.05 vs IpcPH-HFpEF. Other abbreviations as in 
Figure 1. 
 
Figure 3: Ventricular interdependence with exercise in CpcPH-HFpEF. (A) Increase 
in venous return during exercise was associated with more dramatic increase in right 
atrial pressure (RAP) in CpcPC-HFpEF compared to the other HFpEF groups. (B) While 
patients with Non PH-HFpEF and IpcPH-HFpEF displayed an increase in left ventricular 
transmural pressure (LVTMP), CpcPH-HFpEF developed a paradoxical decrease in 
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LVTMP as venous return to the right heart increased during exercise. (C-D) The 
reduction in LVTMP was increased as exercise PVR and transpulmonary gradient 
(TPG) increased, indicating that left heart underfilling was directly related to the severity 
of pulmonary vascular disease. Error bars reflect SEM. †p<0.05 vs Non PH-HFpEF; and 
#p<0.05 vs IpcPH-HFpEF. Other abbreviations as in Figure 1.  
 
Figure 4: Stroke volume reserve and right ventricular stroke work in HFpEF. (A) 
Compared with IpcPH-HFpEF, RAP was increased to greater extent as PA compliance 
decreased in CpcPH-HFpEF. (B) Patients with CpcPH developed a significant increase 
in RAP/PCWP ratio. (C) In CpcPH-HFpEF, stroke volume was decreased during 
exercise, coupled with an increase in PA pulse pressure. (D) RV systolic reserve was 
impaired in both of the PH-HFpEF groups, manifest by a blunted ability to augment RV 
stroke work index (RVSWi) during exercise.   
Error bars reflect SEM. †p<0.05 vs Non PH-HFpEF; and #p<0.05 vs IpcPH-HFpEF. 




Table 1: Baseline Characteristics 











Age (years) 65±13 68±11 70±11 0.4 
Female, n (%) 13 (62%) 60 (63%) 29 (64%) 1.0 
Body mass index (kg/m2) 34±10 35±8 32±6 0.2 
Body surface area (m2) 2.02±0.32 2.05±0.29 1.99±0.22 0.5 
Comorbidities     
Hypertension 17 (89%) 82 (92%) 36 (93%) 0.8 
Coronary artery disease 6 (29%) 32 (34%) 13 (31%) 0.9 
Atrial fibrillation 2 (10%) 30 (32%)† 27 (61%)†# <0.0001 
Diabetes mellitus 2 (10%) 31 (33%) 11 (25%) 0.1 
Sleep apnea syndrome 6 (32%) 37 (51%) 20 (59%) 0.2 
Medications     
ACEI or ARB 10 (48%) 42 (44%) 20 (45%) 1.0 
Beta-blocker 11 (52%) 59 (62%) 25 (57%) 0.7 
Diuretics 11 (52%) 56 (59%) 30 (68%) 0.4 
Laboratories     
Hemoglobin (gm/dl) 12.3±1.5 12.1±1.6 12.1±1.7 0.9 
NT-proBNP (pg/ml) 203 (60, 713) 809 (225, 1407) 1056 (502, 2223)† 0.009 
Pulmonary Function Testing     
Vital Capacity (% predicted) 90±11 79±15 78±15 0.1 
FVC (% predicted) 83±16 79±15 76±15 0.3 
FEV1 (% predicted) 77±19 74±17 67±15 0.1 
Echocardiography     
LV ejection fraction (%) 63±4 62±6 62±6 0.8 
LVEDD (mm) 48±5 48±5 49±6 0.7 
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LV mass index (g/m2) 85±16 96±24 95±23 0.2 
LA volume index (ml/m2) 38±23 40±12 45±17 0.2 
E/e’ 10.0 (8.8, 11.5) 13.9 (10.0, 20.0)† 16.0 (13.0, 20.9)† 0.001 
TV s’ (cm/s) 12±2 12±2 12±3 0.7 
Fractional area change (%) 51±5 49±9 44±11†# 0.02 
RV end-diastolic area (cm/m2) 6.8±1.3 7.3±2.1 8.3±3.1 0.3 
RV basal diameter (mm) 33±5 34±8 37±8 0.1 
RV mid diameter (mm) 25±3 26±7 29±9 0.1 
Moderate or Severe TR (%) 2 (10%) 18 (19%) 17 (38%)†# 0.02 
LV eccentricity index 1.05±0.13 1.05±0.18 1.08±0.16 0.7 
 
Data are mean ± standard deviation, median (25th, 75th percentile), or n (%). Final column reflects overall group 
differences.   
†p<0.05 vs Non PH-HFpEF and #p<0.05 vs IpcPH-HFpEF. 
ACEI indicates angiotensin-converting enzyme inhibitors; ARB, angiotensin-receptor blockers; CpcPH combined post- 
and pre-capillary pulmonary hypertension; eGFR, estimated glomerular filtration rate; FEV1, forced expiratory volume in 
one second; FVC, forced vital capacity; IpcPH isolated post-capillary pulmonary hypertension; LA left atrial; LV, left 
ventricular; LVEDD, left ventricular end-diastolic dimension; NT-proBNP, N-terminal pro-B-type natriuretic peptide; PH, 




Table 2: Resting hemodynamics 











Vital signs     
Heart rate (bpm) 65±12 63±11 62±14 0.6 
Systolic BP (mmHg) 155±25 153±33 159±29 0.7 
Mean BP (mmHg) 103±13 103±18 105±18 0.9 
Central pressures     
RA pressure (mmHg) 10±4 12±4 13±5 0.1 
RA v wave pressure (mmHg) 11±4 14±4† 14±5† 0.02 
PA systolic pressure (mmHg) 36±11 46±11† 60±12†# <0.0001 
PA mean pressure (mmHg) 21±4 31±6† 39±6†# <0.0001 
PCWP (mmHg) 18±4 21±5† 20±4 0.03 
RAP/PCWP ratio 0.56±0.19 0.59±0.17 0.63±0.18 0.3 
LVTMP (mmHg) 8.2±4.2 8.9±4.5 7.6±3.9 0.3 
Vascular and ventricular function 
SVR (dynes/sec*cm5) 1441±446 1418±519 1809±713# 0.01 
TAC (ml/mmHg) 1.1±0.3 1.2±1.0 0.9±0.3# 0.01 
Ea-S (mmHg/ml) 1.8±0.4 1.7±0.7 2.3±0.9# 0.003 
PVR (dynes/sec*cm5) 67±50 154±53† 356±103†# <0.0001 
TPR (mmHg*min/l) 4.49±1.46 6.12±1.78† 9.63±2.22†# <0.0001 
PAC (ml/mmHg) 3.9±1.1 4.0±3.0 2.2±0.8†# 0.0003 
Ea-P (mmHg/ml) 0.40±0.09 0.50±0.19† 0.81±0.25†# <0.0001 
RVSW index (g/m2*beat) 5.7±3.8 11.3±4.5† 12.8±5.6† <0.0001 
Flow measures and metabolism 
Stroke volume index (ml/m2) 40±11 44±13 36±11# 0.004 
Cardiac index (l/min/m2) 2.6±0.7 2.7±0.6 2.2±0.6†# <0.0001 
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O2 consumption (ml/min/kg) 2.6±0.8 2.5±0.6 2.4±0.5 0.4 
A-V O2 difference (ml/dl) 4.7±0.9 4.5±1.2 5.2±1.2# 0.005 
 
Data are mean ± standard deviation. Final column reflects overall group differences.   
†p<0.05 vs Non PH-HFpEF and #p<0.05 vs IpcPH-HFpEF. 
BP, blood pressure; Ea, effective arterial elastance; LVTMP, left ventricular transmural pressure; PA, pulmonary artery; 
PAC pulmonary arterial compliance; PCWP, pulmonary capillary wedge pressure; PVR, pulmonary vascular resistance; 
RA, right atrial; RAP right atrial pressure; RVSW right ventricular stroke work; SVR, systemic vascular resistance; TAC, 














Table 3: Exercise hemodynamics 











Work load (watts) 42±20 32±15† 31±14† 0.03 
O2 consumption (ml/min/kg) 10.5±4.6 8.2±2.5† 7.6±2.2† 0.003 
Vital signs     
Heart rate (bpm) 102±25 93±20 101±23 0.1 
Systolic BP (mmHg) 195±33 182±39 177±43 0.4 
Mean BP (mmHg) 124±19 118±24 114±25 0.5 
Central pressures     
RA pressure (mmHg) 17±6 22±6† 26±8†# <0.0001 
RA v wave pressure (mmHg) 18±9 26±7† 29±9† 0.0005 
PA systolic pressure (mmHg) 54±13 68±14† 82±19†# <0.0001 
PA mean pressure (mmHg) 39±8 48±8† 59±11†# <0.0001 
PCWP (mmHg) 30±5 34±6 32±7 0.1 
RAP/PCWP ratio 0.55±0.18 0.64±0.16 0.84±0.27†# <0.0001 
LVTMP (mmHg) 13.1±5.1 12.6±6.5 6.2±9.0†# 0.0003 
Vascular and ventricular function 
SVR (dynes/sec*cm5) 1016±261 1041±366 1221±556 0.2 
TAC (ml/mmHg) 0.9±0.5 1.0±0.5 0.4±0.9# 0.01 
Ea-S (mmHg/ml) 2.1±0.9 2.1±0.9 2.7±1.1# 0.02 
PVR (dynes/sec*cm5) 106±74 158±90 356±158†# <0.0001 
TPR (mmHg*min/l) 4.94±2.02 6.57±2.32 10.2±3.67†# <0.0001 
PAC (ml/mmHg) 2.9±1.2 2.3±1.0 1.4±0.5†# <0.0001 
Ea-P (mmHg/ml) 0.63±0.32 0.77±0.32 1.30±0.55†# <0.0001 




Stroke volume index (ml/m2) 49±17 44±14 32±9†# <0.0001 
Cardiac index (l/min/m2) 4.7±1.4 3.9±1.1† 3.2±1.0†# <0.0001 
A-V O2 difference (ml/dl) 9.5±2.1 9.8±2.6 10.6±2.1 0.3 
Data are mean ± standard deviation. Final column reflects overall group differences.   
†p<0.05 vs Non PH-HFpEF and #p<0.05 vs IpcPH-HFpEF. Abbreviations as in tables 1 and 2. 
